NFE2L2 and myelodysplastic syndrome: The findings could identify the Keap1-Nrf2-ARE pathway as a potential therapeutic target for managing MDS-related anemia.<h4>International registered report identifier (irrid)</h4>DERR1-10.2196/77936.